Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
June 11, 2001
- Sankyo's Olmesartan More Effective than Other ARBs: Study
June 11, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
June 11, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 11, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -3-
June 11, 2001
- Proposed Drug Classification Gives Top Priority to Clinical Usage
June 11, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -4-
June 11, 2001
- Implementation Working Group Formed for Coordinated Application of CTD
June 11, 2001
- EMA Demands Acceptance of "Moth-eaten Applications"
June 4, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 4, 2001
- Pricing Organization Accepts Eli Lilly Japan's Objection
June 4, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 4, 2001
- REGULATORY NEWS IN BRIEF
June 4, 2001
- DIAGNOSTIC NEWS IN BRIEF
June 4, 2001
- Kowa Licenses Antidiabetic Drug from Roche
June 4, 2001
- MEDICAL DEVICE NEWS IN BRIEF
June 4, 2001
- Life-cycle Management of Adalat Is Successful: Dr Ebsworth of Bayer
June 4, 2001
- Mitsubishi-Tokyo, Welfide Sign Merger Contract
June 4, 2001
- FY2000 Business Reports Show Large Gap between Poor and Excellent Performers
June 4, 2001
- BULLETIN
June 4, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…